Publication Date:
2016
Abstract:
In recent years, serum uric acid (SUA) as a determinant of cardiovascular (CV) risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia SUA are at increased risk of cardiac, renal and vascular damage and CV events. There is now some evidence to suggest that urate-lowering treatment may reduce CV risk in this group and, thus, may represent a new strategy in risk reduction.
CRIS type:
1.1 Articolo in rivista
Keywords:
AF; CV disease; Heart failure; Target organ damage; Uric acid; Xanthine-oxidase inhibitors
List of contributors:
Muiesan, M. L.; Agabiti-Rosei, C.; Paini, A.; Salvetti, M.
Published in: